Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ORGANIZATION
ORGANIZATION
- JMA Sets Up “Council on Medical COI” Out of Concerns Over Transparency GL
January 11, 2013
- JPWA Chief Bessho Calls for Clearer Rule for Sales Tax on Ethical Drugs
January 10, 2013
- Efforts to Promote Generic Substitution Preferable to Cutting Prices of Long-Listed Drugs: Mr Sawai of JGA
January 8, 2013
- Member Companies to Begin Enforcing New COP in FY2013: JPMA President Teshirogi
January 7, 2013
- JPMA to Ask Abe Administration to Continue Former Dialogue with Pharmaceutical Industry: Dr Teshirogi
January 7, 2013
- NHO to Review Calculation Method for Clinical Trial Costs
December 28, 2012
- JPA to Hold Workshops to Train Pharmacists to Make Clinical Assessments Based on Subjective Symptoms
December 26, 2012
- JMA to Discuss JPMA’s Transparency Guidelines with JPMA, Related Medical Organizations
December 25, 2012
- “New Administration Needed to Allocate Personnel to Cabinet, LDP to Work Out Challenges”: Keizai Doyukai Chair Hasegawa
December 19, 2012
- Generic Market Share at 25.4% in 2nd Quarter on Volume Basis: JGA
December 14, 2012
- Tohoku Pharmaceutical Univ. to Acquire Tohoku Kosei Nenkin Hospital, Aiming to Turn It into Model Hospital for Pharmaceutical Education
December 14, 2012
- Panelists at IGPA Conference Express Concern that FTA Could Strengthen Intellectual Property Rights
December 10, 2012
- GIST Patients Group Submits Petition Calling for Early Filing for Regorafenib for GIST
December 10, 2012
- Kyoto Declaration Calls for Strict Quality Control of Generics: IGPA Annual Conference
December 10, 2012
- Biosimilars Popular Topic at IGPA Annual Conference
December 10, 2012
- Ways to Deal with Biosimilars Will Be Common Challenge Among Generics Companies: JGA President Sawai
December 6, 2012
- Drug Costs Should Be Basically Borne by Patients under Compassionate Use System: JPMA’s Kuwahara
December 5, 2012
- 80 Medical Institutions Submit Comprehensive Agreements on Info Disclosure in Response to JPMA Transparency GLs
December 4, 2012
- Top Officials of FPMAJ, JGA Disagree on Progress in Generic Drug Use at CSIMC Expert Subcommittee Meeting
November 30, 2012
- Pharmaceutical Makers to Reap Equal Benefits from Premium for New Drug Development in Long Run: FPMAJ Chief Naito
November 29, 2012
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…